# GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition

> **NCT03616509** · PHASE4 · COMPLETED · sponsor: **Corporacion Parc Tauli** · enrollment: 30 (actual)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** Growth hormone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03616509
- **Lead sponsor:** Corporacion Parc Tauli
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-19
- **Primary completion:** 2019-07-26
- **Final completion:** 2019-07-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616509, "GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03616509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*